Detail of "192391-48-3"
- CAS Number:
- 192391-48-3
- Name:
ImmunoglobulinG2a, anti-(human CD20 (antigen)) (mouse monoclonal clone B1R1 g2a-chain),disulfide with mouse monoclonal clone B1R1 lx-chain, dimer, iodine-131I-labeled
- Synonyms:
- 3:PN: WO2008003319 PAGE: 45 claimed sequence; Bexxar; Iodine I131 tositumomab;Tositumab
ImmunoglobulinG2a, anti-(human CD20 (antigen)) (mouse monoclonal clone B1R1 g2a-chain),disulfide with mouse monoclonal clone B1R1 lx-chain, dimer, iodine-131I-labeled
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers
will soon contact you!
*Required Fields
Reference
- Recent advance in radioimmunotherapy for B-cell lymphoma
- All Rights Reserved. Recent advance in radioimmunotherapy for B-cell lymphoma. 206181-63-7 and 192391-48-3 are cas registry numbers. These chemicals are also mentioned in this article. Watanabe, Takashi (Hematology Division, National Cancer Center Hospital, Tokyo 104-0045, Japan). Ketsueki, Shuyoka, 52(4), 377-381 (Japanese) 2006 Kagaku Hyoronsha. CODEN: KETSBI. ISSN: 0915-8529. DOCUMENT TYPE: Journal; General Review CA Section: 8 (Radiation Biochemistry) Section cross-reference(s): 15 A review, discussing recent advance in radioimmunotherapy for B-cell lymphoma with radioactive tositumomab (Bexxar) and ibritunomab (Zevalin). .

